公开(公告)号：US11458135B2

公开(公告)日：2022-10-04

申请号：US16099161

申请日：2016-08-03

Applicant: SUVEN LIFE SCIENCES LIMITED

Inventor： Ramakrishna Nirogi ,  Anil Karbhari Shinde ,  Pradeep Jayarajan ,  Gopinadh Bhyrapuneni ,  Ramasastri Kambhampati ,  Venkateswarlu Jasti

IPC: A61K31/496 ,  A61P25/28 ,  A61K31/445 ,  A61K31/31 ,  A61P25/18 ,  A61P25/16

Abstract: The present invention relates to pure 5-HT6 receptor antagonists, or the pharmaceutically acceptable salt(s) thereof in combination with or as adjunct to acetylcholinesterase inhibitors and their use in the treatment of cognitive disorders. The invention further provides the pharmaceutical composition containing the said combination.

公开(公告)号：US08859003B2

公开(公告)日：2014-10-14

申请号：US12976614

申请日：2010-12-22

Applicant: Ahmad Akashe ,  Anilkumar Ganapati Gaonkar ,  Les Lawrence ,  Amado R. Lopez ,  George W. Haas ,  Dana Sebesta ,  Yan Wang

Inventor： Ahmad Akashe ,  Anilkumar Ganapati Gaonkar ,  Les Lawrence ,  Amado R. Lopez ,  George W. Haas ,  Dana Sebesta ,  Yan Wang

IPC: A61K9/16 ,  A61K9/00 ,  A61K31/045 ,  A61K8/92 ,  A23L2/39 ,  A61K31/31 ,  A61Q13/00 ,  A61K31/015 ,  A61K31/05 ,  A23L1/22 ,  A61K8/11 ,  A61K9/50 ,  A61K8/64 ,  A23L2/52 ,  A23L1/00

CPC classification number: A61K9/0095 ,  A23L2/39 ,  A23L2/52 ,  A23L27/72 ,  A23P10/35 ,  A61K8/11 ,  A61K8/645 ,  A61K8/927 ,  A61K9/5015 ,  A61K9/5052 ,  A61K31/015 ,  A61K31/045 ,  A61K31/05 ,  A61K31/31 ,  A61K2800/412 ,  A61Q13/00 ,  A61K2300/00

Abstract: Hydrophobic liquids are microencapsulated by an enteric matrix in an environment substantially free of organic solvents. The process includes forming an emulsion of the enteric material and hydrophobic liquid in water, titrating the emulsion with an acid to form a particulate precipitate and optionally coating the particulate with a combination of enteric material and plasticizer.

Abstract translation: 疏水液体在基本上不含有机溶剂的环境中被肠溶基质微胶囊化。 该方法包括在水中形成肠溶性物质和疏水性液体的乳液，用酸滴定乳液以形成颗粒沉淀物，并任选地用肠溶性物质和增塑剂的组合物包被颗粒。

公开(公告)号：US08357719B2

公开(公告)日：2013-01-22

申请号：US12531875

申请日：2007-11-22

Applicant: Chur Chin

Inventor： Chur Chin

IPC: A01N55/02 ,  A01N55/06 ,  A61K31/31 ,  C07F1/00 ,  C22C5/02 ,  C01G3/00 ,  C01G5/00 ,  C01G7/00 ,  C22B11/00 ,  C22B15/00

CPC classification number: A61K33/24 ,  A61K9/0019 ,  A61K31/14 ,  A61K47/6923

Abstract: A drug having a muscle relaxing effect can be prepared by binding negatively charged gold nanoparticles having a size of 1.4 nm fitted to synaptic clefts to choline through ionic bonds, thereby inducing gold-sulfur bonds in the Cys loop of an acetylcholine receptor in neuromuscular junction, and thus blocking the electric current induced in signal transduction from a nerve to a muscle, thereby blocking neuromuscular transmission chemically and physically. When the reverse is administered after surgery, the gold-sulfur bonds are broken due to the re-flow of the electric current, and thus the gold nanoparticles are again released and metabolized into neuromuscular junction. Further, such muscle relaxing effect can be applied as an anticonvulsant.

Abstract translation: 具有肌肉松弛作用的药物可以通过将具有1.4nm大小的带负电荷的金纳米颗粒与突触裂缝配合以通过离子键胆碱来制备，从而在神经肌肉接头中的乙酰胆碱受体的Cys环中诱导金 - 硫键， 从而阻断从神经到肌肉的信号转导中诱发的电流，从而阻断神经肌肉的化学和物理传递。 手术后反复给药时，由于电流的再流动，金 - 硫键断裂，金纳米颗粒再次释放并代谢成神经肌肉接头。 此外，这种肌肉松弛效果可以用作抗惊厥药。

公开(公告)号：US07354604B2

公开(公告)日：2008-04-08

申请号：US10712990

申请日：2003-11-17

Applicant: Jose A. Ramirez ,  Navid Omidbakhsh

Inventor： Jose A. Ramirez ,  Navid Omidbakhsh

IPC: A61K33/40 ,  A61K31/31 ,  A61K31/34 ,  A61K31/60

CPC classification number: A01N59/00 ,  A01N59/14 ,  A01N2300/00 ,  A01N43/08 ,  A01N37/40 ,  A01N37/10 ,  A01N31/08 ,  A01N25/30

Abstract: An aqueous disinfecting solution and dry powdered composition which may be dissolved in water to provide the solution. The solution has a pH of from 0.6 to 7 and comprises (a) hydrogen peroxide in a concentration of from 0.01 to 6% w/w; and (b) at least one component chosen from cyclic carboxylic acids and aromatic alcohols, in a concentration of from 0.01 to 4 w/w %, all based on the total weight of the solution. The cyclic carboxylic acids are preferably 2-furan carboxylic acid, benzoic acid and salicylic acid. Furthermore, the solution preferably contains at least one C6-C12 alkyl diphenyl oxide sulfonate surfactant and a nonionic surfactant. Additional optional ingredients include anionic surfactants, corrosion inhibitors, cation sequestering agents, and buffers.

Abstract translation: 水溶性消毒溶液和干粉组合物，其可以溶解在水中以提供溶液。 该溶液具有0.6至7的pH，并且包含（a）浓度为0.01至6％w / w的过氧化氢; 和（b）选自环状羧酸和芳族醇的至少一种组分，其浓度为0.01至4w / w％，均基于溶液的总重量。 环状羧酸优选为2-呋喃羧酸，苯甲酸和水杨酸。 此外，该溶液优选含有至少一种C6-C12烷基二苯基氧化物磺酸盐表面活性剂和非离子表面活性剂。 另外的任选成分包括阴离子表面活性剂，腐蚀抑制剂，阳离子螯合剂和缓冲剂。

公开(公告)号：US6096785A

公开(公告)日：2000-08-01

申请号：US690476

申请日：1996-07-30

Applicant: Heinz Schneider

Inventor： Heinz Schneider

IPC: A61K31/195 ,  A23L1/305 ,  A61K31/198 ,  A61K31/436 ,  A61K31/70 ,  A61K38/00 ,  A61K38/13 ,  A61K45/06 ,  A61P13/12 ,  A61K31/31

CPC classification number: A61K45/06 ,  A23L33/175 ,  A61K31/198 ,  A61K31/436 ,  A61K38/13

Abstract: A method for the use of at least one amino acid selected from the group consisting of glycine, alanine and serine, or the physiologically acceptable salts thereof (component (a)), in the preparation of a medicament or nutritional formulation for the prophylaxis and/or therapy of renal dysfunction induced by cyclosporins or ascomycins.

Abstract translation: 使用选自甘氨酸，丙氨酸和丝氨酸的至少一种氨基酸或其生理学上可接受的盐（组分（a））的方法，用于制备用于预防和/ 或治疗由环孢菌素或ascomycins诱导的肾功能障碍。

公开(公告)号：US4277491A

公开(公告)日：1981-07-07

申请号：US965267

申请日：1978-12-01

Applicant: Carmelo Gandolfi ,  Carlo Passarotti ,  Alessandro Andreoni ,  Angelo Fumagalli ,  Franco Faustini ,  Roberto Ceserani ,  Maria M. Usardi

Inventor： Carmelo Gandolfi ,  Carlo Passarotti ,  Alessandro Andreoni ,  Angelo Fumagalli ,  Franco Faustini ,  Roberto Ceserani ,  Maria M. Usardi

IPC: A61K31/31 ,  A61K31/41 ,  A61P43/00 ,  C07C405/00 ,  C07D307/935 ,  C07D307/937 ,  C07D407/12 ,  A61K31/557

CPC classification number: C07D307/937 ,  C07C405/00 ,  Y10S514/822 ,  Y10S514/826 ,  Y10S514/926 ,  Y10S514/927 ,  Y10S514/929

Abstract: Bicyclic prostaglandins and pharmaceutical and veterinary compositions containing them having numerous pharmaceutical or veterinary utilities including, for example, hypotensive, vasodilatory, anti-aggregating, luteolytic, and cytoprotective activities. Processes for preparing the compounds are also disclosed.

Abstract translation: 双环前列腺素和含有它们的药物和兽药组合物具有许多药物或兽医用途，包括例如降血压，血管扩张，抗聚集，溶血性和细胞保护活性。 还公开了制备化合物的方法。

公开(公告)号：US09730910B2

公开(公告)日：2017-08-15

申请号：US14510321

申请日：2014-10-09

Applicant: Vanda Pharmaceuticals, Inc.

Inventor： Marlene Michelle Dressman ,  John Joseph Feeney ,  Louis William Licamele ,  Mihael H. Polymeropoulos

IPC: A61K31/343 ,  A61K45/06 ,  A61K31/31 ,  A61K31/496 ,  A61K31/15 ,  A61K31/277 ,  G06F19/00

CPC classification number: A61K31/343 ,  A61K31/15 ,  A61K31/277 ,  A61K31/31 ,  A61K31/496 ,  A61K45/06 ,  G06F19/00 ,  G16H10/60 ,  Y02A90/26 ,  A61K2300/00

Abstract: Embodiments of the invention relate to the use of a melatonin agonist in the treatment of free running circadian rhythms in patients, including light perception impaired patients, e.g., blind patients, and to methods of measuring circadian rhythm.

公开(公告)号：US08877763B2

公开(公告)日：2014-11-04

申请号：US13841827

申请日：2013-03-15

Applicant: Genosco ,  Oscotec, Inc.

Inventor： Hong Woo Kim ,  Hee Kyu Lee ,  Ho-Juhn Song ,  Jaekyoo Lee ,  Jong Sung Koh ,  Jung-Ho Kim ,  Se Won Kim ,  In Yong Lee

IPC: A01N43/90 ,  A61K31/519 ,  A61K45/06 ,  C07D471/04 ,  C07D487/04 ,  C07D239/00 ,  A61K31/31

CPC classification number: A61K31/519 ,  A61K31/31 ,  A61K45/06 ,  C07D239/00 ,  C07D471/04 ,  C07D487/04

Abstract: Compounds of Formula (I) and methods for inhibiting kinases, including spleen tyrosine kinases, are disclosed. Also disclosed are methods for treating a kinase-mediated disease or condition by administering to a subject a therapeutically effective amount of the compound of Formula (I).

Abstract translation: 公开了式（I）化合物和抑制激酶的方法，包括脾脏酪氨酸激酶。 还公开了通过向受试者施用治疗有效量的式（I）化合物来治疗激酶介导的疾病或病症的方法。

公开(公告)号：US20130060208A1

公开(公告)日：2013-03-07

申请号：US13517406

申请日：2010-12-21

Applicant: Michael Christian Givskov ,  Thomas Bjarnsholt ,  Klaus Kirketerp-Møller

Inventor： Michael Christian Givskov ,  Thomas Bjarnsholt ,  Klaus Kirketerp-Møller

IPC: A61K31/19 ,  A61K31/47 ,  A61K31/546 ,  A61K31/65 ,  A61K31/424 ,  A61K38/02 ,  A61K31/7036 ,  A61K31/575 ,  A61K31/345 ,  A61K31/31 ,  A61K31/4425 ,  A61K33/06 ,  A61K31/79 ,  A61K33/20 ,  A61P17/02 ,  A61P31/04 ,  A61M1/00 ,  A61M35/00 ,  A61K31/7028

CPC classification number: A61K9/0014 ,  A61F13/00068 ,  A61L15/46 ,  A61L26/0066 ,  A61L26/0076 ,  A61L2300/404 ,  A61L2300/406 ,  A61M1/0088 ,  A61M27/00

Abstract: The present invention relates to wound care products, devices and methods incorporating acetic acid for the treatment of bacterial infections, in particular bacterial biofilm infections. In particular it relates to a wound care product comprising acetic acid, wherein the product comprises at least one further antibacterial compound; a delivery system comprising a container connected to a means of delivery which is connected to a pad, wherein said container comprises a composition comprising acetic acid and said pad comprises a self-adhesive material; a kit comprising a dressing and an adhesive membrane, wherein the dressing comprises a composition comprising acetic acid; a method of treating a wound comprising a) applying acetic acid to the wound and b) applying a negative pressure to the wound.

Abstract translation: 本发明涉及包含乙酸用于治疗细菌感染，特别是细菌生物膜感染的伤口护理产品，装置和方法。 特别地，其涉及包含乙酸的伤口护理产品，其中该产品包含至少一种其它抗菌化合物; 输送系统，包括连接到输送装置的容器，所述容器连接到垫，其中所述容器包括包含乙酸的组合物，所述垫包括自粘合材料; 包括敷料和粘合剂膜的试剂盒，其中所述敷料包含包含乙酸的组合物; 一种治疗伤口的方法，包括：a）向伤口施用乙酸，b）向伤口施加负压。

公开(公告)号：US07045540B2

公开(公告)日：2006-05-16

申请号：US11152888

申请日：2005-06-15

Applicant: Robert F. Kaltenbach ,  Simon P. Robinson ,  George L. Trainor

Inventor： Robert F. Kaltenbach ,  Simon P. Robinson ,  George L. Trainor

IPC: A61K31/31 ,  C07D257/04

CPC classification number: C07D257/04 ,  C07C51/487 ,  C07C57/50 ,  C07C59/54 ,  C07C59/72 ,  C07C69/618 ,  C07C69/734 ,  C07C255/34 ,  C07C311/51 ,  C07C2601/10 ,  C07C2602/10 ,  C07C2602/12 ,  C07D277/80 ,  C07D311/58 ,  C07D333/34

Abstract: The present invention provides, inter alia, triphenylethylene derivatives, such as, 5-{2-[4-(1,2-Diphenyl-but-1-enyl)-phenyl]-vinyl}-1H-tetrazole, as selective estrogen receptor modulators. Also provided are methods for treating estrogen stimulated diseases in mammals including, but not limited to, for example, breast, uterine, ovarian, prostate and colon cancer; osteoporosis; endometriosis; uterine fibroid; Alzheimer's disease; macular degeneration; urinary incontinence; and type II diabetes, as well as, pharmaceutical compositions comprising at least one compound of the present invention.

Abstract translation: 本发明特别提供三苯基乙烯衍生物，例如5- {2- [4-（1,2-二苯基 - 丁-1-烯基） - 苯基] - 乙烯基} -1H-四唑，作为选择性雌激素受体 调制器 还提供了用于治疗哺乳动物中雌激素刺激的疾病的方法，包括但不限于例如乳腺癌，子宫癌，卵巢癌，前列腺癌和结肠癌; 骨质疏松症 子宫内膜异位症 子宫肌瘤 阿尔茨海默氏病; 黄斑变性; 尿失禁 和II型糖尿病，以及包含至少一种本发明化合物的药物组合物。